In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
The in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
Malay
Sheila
S
Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098, USA.
Roblin
Patricia M
PM
Reznik
Tamara
T
Kutlin
Andrei
A
Hammerschlag
Margaret R
MR
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002692:Chlamydia trachomatis / Q000187:drug effects*; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D024841:Fluoroquinolones; D006801:Humans; D007211:Indoles; D008826:Microbial Sensitivity Tests; D015363:Quinolones
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; C419689:garenoxacin